Minerva Surgical, Inc.

As of May 11, 2022, Minerva Surgical, Inc. is rated as risky due to its overvaluation and poor financial metrics, including a P/E ratio of 0.00 and a one-year return of -99.17%, significantly underperforming compared to its peers and the S&P 500.

As of May 11, 2022, Minerva Surgical, Inc. is considered a risky investment due to its poor financial metrics, including a P/E ratio of 0.00 and significant underperformance with a -99.09% return over the past year, indicating it may be overvalued compared to its peers.

As of June 13, 2025, the market trend is neutral with mixed indicators, showing mildly bullish momentum on weekly and monthly MACD, but a mildly bearish sentiment from daily moving averages and no clear trend in RSI or KST.

As of Jun 18, Minerva Surgical, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap, with net sales of 51.68 million and a net profit loss of 33.45 million over the latest four quarters. As of Dec 22, the company's shareholder's funds were 17.18 million, and total assets were 68.90 million.